Get the Stockscreener App
3.78
0.80%
0.03
After Hours:
3.77
-0.010
-0.26%
Ac Immune Sa stock is traded at $3.78, with a volume of 91,541.
It is up +0.80% in the last 24 hours and up +17.03% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.75
Open:
$3.56
24h Volume:
91,541
Relative Volume:
0.61
Market Cap:
$370.04M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-4.4262
EPS:
-0.854
Net Cash Flow:
$-68.17M
1W Performance:
+3.28%
1M Performance:
+17.03%
6M Performance:
+27.70%
1Y Performance:
+32.63%
1-Day Range:
$3.54
$3.82
1-Week Range:
$3.54
$3.93
52-Week Range:
$2.20
$5.14
Ac Immune Sa Stock (ACIU) Company Profile
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
Down Syndrome Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | AstraZeneca, Aelis Farma, AC Immune SA, Eisai Inc., Hoffmann-La Roche, Life Molecular Imaging SA - Barchart
CompleCure, AGC Biologics Partner To Develop Advanced Anti-Cancer Therapy - Contract Pharma
CompleCure Partners with AGC Biologics’ Chiba Site to Develop Advanced Anti-Cancer Therapeutic Using Pioneering AMDC Technology - AccessWire
Investment Analysts’ Upgrades for September 23rd (ACIU, APD, BBY, BLD, CIGI, DQ, EBR, GFF, HBNC, KOPN) - Defense World
AGC Biologics and CompleCure Collaborate on Innovative Breast Cancer Treatment - Vancity Buzz
Bulls beat South and advance to Australia Cup final - MSN
AC Immune SA Welcomes New CMO Dr. Anke Post - TipRanks
AC Immune (NASDAQ:ACIU) Given Buy Rating at HC Wainwright - Defense World
Investment Analysts’ Updated EPS Estimates for September 18th (ACIU, ADAG, AMS, AOSL, BDTX, BRCC, CFLT, CGEM, CMP, COR) - Defense World
AC Immune (NASDAQ:ACIU) Earns Buy Rating from HC Wainwright - MarketBeat
AC Immune shares hold as analyst reiterates price target - Investing.com
AC Immune secures milestone payment for Alzheimer's trial - Investing.com
AC Immune Advances in Alzheimer’s Trial, Secures Funding - TipRanks
AC Immune receives second milestone payment for ACI-35.030 - TipRanks
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - Yahoo Finance UK
A novel class of drug candidates for neurodegenerative diseases - Drug Target Review
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions - Yahoo Finance UK
AC Immune SA (NASDAQ:ACIU) Short Interest Update - MarketBeat
AC Immune's Tau-PET diagnostic gets FDA fast track - Investing.com
AC Immune’s Diagnostic Achieves FDA Fast Track Status - TipRanks
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions - StockTitan
FDA grants AC Immune’s PI-2620 Tau-PET diagnostic fast track designations - TipRanks
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions - Yahoo Finance
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
The past three years for AC Immune (NASDAQ:ACIU) investors has not been profitable - Yahoo Finance
Assenagon Asset Management S.A. Purchases 328,312 Shares of AC Immune SA (NASDAQ:ACIU) - MarketBeat
AC Immune (NASDAQ:ACIU) Shares Cross Below 50-Day Moving Average of $3.84 - MarketBeat
AC Immune (NASDAQ:ACIU) Share Price Passes Below Fifty Day Moving Average of $3.84 - Defense World
HC Wainwright Equities Analysts Raise Earnings Estimates for AC Immune SA (NASDAQ:ACIU) - Defense World
Q3 2024 EPS Estimates for AC Immune SA Cut by Analyst (NASDAQ:ACIU) - Defense World
HC Wainwright Brokers Raise Earnings Estimates for AC Immune SA (NASDAQ:ACIU) - MarketBeat
AC Immune SA to Post FY2028 Earnings of $0.10 Per Share, Leerink Partnrs Forecasts (NASDAQ:ACIU) - Defense World
AC Immune SA Expected to Earn FY2025 Earnings of $0.33 Per Share (NASDAQ:ACIU) - Defense World
AC Immune SA (NASDAQ:ACIU) Forecasted to Earn FY2028 Earnings of $0.10 Per Share - MarketBeat
We Might See A Profit From AC Immune SA (NASDAQ:ACIU) Soon - Simply Wall St
AC Immune: Q2 Earnings Snapshot - San Antonio Express-News
NeuroVoices: Stina Saunders, PhD, on the Utility of the Electronic Person-Specific Outcome Measure on Brain Health - Neurology Live
AC Immune SA Announces $80M Open Market Sales Plan - TipRanks
AC Immune: Q2 Earnings Snapshot - The Washington Post
Lazard Asset Management LLC Makes New Investment in AC Immune SA (NASDAQ:ACIU) - Defense World
AC Immune: Q2 Earnings Snapshot - Barchart
AC Immune SA Strikes Licensing Deal with Takeda - TipRanks
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - StockTitan
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - Informazione.it
NeurologyLive® Brain Games: August 4, 2024 - Neurology Live
ACIUAC Immune SA Latest Stock News & Market Updates - StockTitan
AC Immune Reveals Pioneering Neurodegenerative Drug Technology - TipRanks
AC Immune reveals new drug candidate for brain diseases - Investing.com
AC Immune reveals new drug candidate for brain diseases By Investing.com - Investing.com Canada
AC Immune reveals new drug candidate for brain diseases - Investing.com India
AC Immune reveals new drug candidate for brain diseases By Investing.com - Investing.com Australia
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):